Primitive Neuroectodermal Tumor — Trials

Primitive Neuroectodermal Tumor — Trials · CancerIndex

Clinical trials

Registered studies

673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 146
Recruiting: 80
Ph III recruiting: 8
Growth YoY: −33.3%
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 151–200 of 266 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01492673	Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma	completed	Phase 2	9	Memorial Sloan Kettering Cancer CenterOTHER	2	Oct 29, 2019	clinicaltrials
NCT01334515	Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma	completed	Phase 2	52	Children's Oncology GroupNETWORK	2	Oct 21, 2019